Loading clinical trials...

Optimizing Dosing Strategies in Oral Iron Supplementation | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Optimizing Dosing Strategies in Oral Iron Supplementation

NCT06238895•Luzerner Kantonsspital

Summary

The goal of this clinical trial is to evaluate, if a change in dosing strategy in oral iron supplementation from leads to an improvement of iron absorption and consequently a faster therapy in patients with iron deficiency. The main question the study aims to answer is: Does a treatment effect (measured by change in hemoglobin after 12 weeks of treatment) exist between daily oral iron supplementation and interval administration (every second day)? Participants will receive oral iron supplementation every second day with double the standard dose (intervention group). Researchers will compare this group with the active control group, that receives oral iron supplementation every day with the standard dose. Participants will present for three patient visits (at baseline, after 6 and after 12 weeks of treatment).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Informed Consent signed by the subject
•≥18 years of age
•Iron deficiency: Ferritin \<30 µg/l
•hemoglobin ≥ 80 g/l
•CRP \< 5 mg/l

Exclusion Criteria

•Refusal of study participation,
•Regular administration of Erythropoietin
•Oral or intravenous iron supplementation \<12 weeks prior to investigation
•Contraindications to intervention medication (Tardyferon), e.g. known hypersensitivity or allergy to iron sulfate / ferrous sulfate
•Blood transfusion or donation \<12 weeks prior to investigation
•Active chemotherapy
•Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject.
•Note
•Due to slow recruitment, the following inclusion criterion was removed on 09/25/2024 (MM/DD/YYYY):
•Anemia (as defined by the WHO): Hemoglobin \<130 g/L for men, Hemoglobin \<120 g/l for women, Hemoglobin \<110 g/l for pregnant women

Locations (1)

Luzerner Kantonsspital

Lucerne, Switzerland

Key Dates

Start Date

March 1, 2024

Primary Completion Date

November 18, 2025

Completion Date

November 18, 2025

Last Updated

January 7, 2026

Enrollment

ACTUAL participants

Conditions

Iron DeficienciesIron Deficiency AnemiaIron Deficiency Anemia Treatment

Interventions

Tardyferon

DRUG

Kids With Iron Deficiency and Scoliosis

NCT06042699

Adolescent Idiopathic ScoliosisNeuromuscular Scoliosis+5 more

View study

RECRUITING

Influences of Long-acting Reversible Contraceptives on Iron Status and Physiological Responses to Extreme Environments in Women

NCT06909695

ContraceptionIron Deficiencies

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 7, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Optimizing Dosing Strategies in Oral Iron Supplementation

Inclusion Criteria

Exclusion Criteria

Kids With Iron Deficiency and Scoliosis

Influences of Long-acting Reversible Contraceptives on Iron Status and Physiological Responses to Extreme Environments in Women

Impact of Benazir Nashonuma Program (BNP) on Maternal and Child Nutritional Status

Nutritional Educational Program On Therapy in Iron Deficiency Anemia

Daily Versus Alternate Day Regimen of Iron Supplementation in Children with Iron Deficiency Anemia

Assessing Clinical Impact of AI for Iron Deficiency